- ISIN
- US50127T1097
- CUSIP
- 50127T109
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 22, 2015
Highlights
- Market Cap
- $919.77M
- Enterprise Value
- $896.50M
- EPS (TTM)
- -$3.35
- Total Revenue (TTM)
- $71.64M
- Gross Profit (TTM)
- $67.71M
- EBITDA (TTM)
- -$304.14M
- Year Range
- $5.45 - $12.49
- Target Price
- $27.33
- ROA (TTM)
- -45.14%
- ROE (TTM)
- -273.05%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
KURA Performance Chart
Kura Oncology, Inc. (KURA) is down 0.1% since the beginning of the year. At $10 per share, KURA is trading 16.9% below its 52-week high of $12. Investors who bought $1,000 worth of KURA shares 5 years ago would now be looking at an investment worth $470.
Loading charts...
Returns By Period
Kura Oncology, Inc. (KURA) has returned -0.10% so far this year and 76.83% over the past 12 months. Over the last decade, KURA has posted an annualized return of 14.42%, slightly higher than the S&P 500 Index benchmark’s 13.71%.
Kura Oncology, Inc.
- 1D
- 0.19%
- 1M
- -7.73%
- YTD
- -0.10%
- 6M
- -3.80%
- 1Y
- 76.83%
- 3Y*
- -1.65%
- 5Y*
- -14.01%
- 10Y*
- 14.42%
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
KURA Monthly Returns History
Based on dividend-adjusted daily data since Nov 5, 2015, KURA's average daily return is +0.10%, while the average monthly return is +1.94%. At this rate, an investment would double in approximately 3.0 years.
Historically, 50% of months were positive and 50% were negative. The best month was Sep 2017 with a return of +107.6%, while the worst month was Jan 2016 at -42.9%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 9 months.
On a daily basis, KURA closed higher 48% of trading days. The best single day was Sep 8, 2017 with a return of +72.3%, while the worst single day was Nov 21, 2024 at -36.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -21.85% | 7.51% | -6.87% | 8.61% | 15.52% | 1.76% | -0.10% | ||||||
| 2025 | -9.18% | -2.53% | -14.40% | -0.61% | -13.26% | 1.41% | 4.85% | 30.58% | 12.03% | 16.05% | 18.21% | -14.42% | 19.29% |
| 2024 | 40.06% | 4.67% | 1.19% | -8.02% | 5.05% | -0.10% | 1.07% | 1.20% | -7.22% | -14.43% | -33.97% | -21.11% | -39.43% |
| 2023 | 11.36% | -13.75% | 2.60% | -20.36% | 36.76% | -20.57% | -1.32% | -4.89% | -8.16% | -7.35% | 14.44% | 48.71% | 15.87% |
| 2022 | 0.64% | 12.63% | 1.32% | -10.76% | -8.29% | 39.29% | -16.48% | -9.47% | -1.44% | 13.62% | 1.61% | -21.31% | -11.36% |
| 2021 | -8.30% | -6.51% | 0.96% | -4.74% | -17.38% | -6.29% | -9.16% | -2.53% | 1.46% | -12.33% | -14.98% | 0.29% | -57.13% |
Benchmark Metrics
Kura Oncology, Inc. has an annualized alpha of 12.11%, beta of 1.11, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since November 05, 2015.
- This stock participated in 146.42% of S&P 500 Index downside but only 104.81% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 12.11%
- Beta
- 1.11
- R²
- 0.08
- Upside Capture
- 104.81%
- Downside Capture
- 146.42%
Return for Risk
Risk / Return Rank
KURA ranks 76 for risk / return — better than 76% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Kura Oncology, Inc. (KURA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| KURA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.50 | ||
| Sortino ratioReturn per unit of downside risk | -0.38 | ||
| Omega ratioGain probability vs. loss probability | 1.23 | 1.32 | -0.09 |
| Calmar ratioReturn relative to maximum drawdown | 1.98 | 2.46 | -0.48 |
| Martin ratioReturn relative to average drawdown | 4.03 | 10.92 | -6.89 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Kura Oncology, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Kura Oncology, Inc. was 86.69%, occurring on Aug 8, 2025. The portfolio has not yet recovered.
The current Kura Oncology, Inc. drawdown is 75.06%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -86.69%Aug 2025 | 4y 7mo | — | 5y 6moDec 2020 - now |
COVID crash2020 | -72.44%Mar 2020 | 2y 14d | 5mo 10d | 2y 5moMar 2018 - Aug 2020 |
2016 bear market2016 | -70.46%Jul 2016 | 7mo 28d | 7mo 29d | 1y 3moNov 2015 - Mar 2017 |
2017 bear market2017 | -45.98%Aug 2017 | 3mo 21d | 24d | 4mo 15dApr 2017 - Sep 2017 |
2017 bear market2017 | -27.00%Mar 2017 | 0s | 1mo 5d | 1mo 5dMar 2017 - Apr 2017 |
Drawdown Indicators
| KURA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -86.69% | -56.78% | -29.91% |
Max Drawdown (1Y)Largest decline over 1 year | -39.04% | -9.10% | -29.94% |
Max Drawdown (3Y)Largest decline over 3 years | -76.46% | -18.90% | -57.56% |
Max Drawdown (5Y)Largest decline over 5 years | -76.46% | -25.43% | -51.03% |
Max Drawdown (10Y)Largest decline over 10 years | -86.69% | -33.92% | -52.77% |
Current DrawdownCurrent decline from peak | -75.06% | -3.21% | -71.85% |
Average DrawdownAverage peak-to-trough decline | -47.33% | -10.71% | -36.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.12% | 2.04% | +17.08% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Kura Oncology, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Kura Oncology, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for KURA relative to other companies in the Biotechnology industry. Currently, KURA has a P/S ratio of 12.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for KURA in comparison with other companies in the Biotechnology industry. Currently, KURA has a P/B value of 8.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with KURA
Add Kura Oncology, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with KURA